Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial

Why this study matters for people with breast cancer

New cancer drugs often look very promising in controlled clinical trials, but many patients and families wonder whether those same results hold true in everyday hospital settings. This study asks that exact question for a widely used drug combination—abemaciclib plus fulvestrant—given to people with a common form of advanced breast cancer in England. By comparing real-life outcomes in the National Health Service (NHS) with those reported in a major trial called MONARCH-2, the researchers explore how well trial results translate into the messier reality of routine care.

Two medicines working together

The paper focuses on patients with advanced breast cancer that is driven by hormones (hormone receptor-positive) and does not have too much of a protein called HER2. For these patients, standard treatment builds on hormone-blocking drugs, often combined with a newer group of medicines called CDK4/6 inhibitors. Abemaciclib is one such inhibitor: it slows down the cell cycle, making it harder for cancer cells to divide. Fulvestrant is an anti-hormone injection that blocks the cancer’s ability to use oestrogen. Together, they aim to keep the disease under control for longer and delay the need for chemotherapy, which is usually harsher and more disruptive to daily life.

How the researchers checked real-world experience

To see how this drug pair performs outside a trial, the team used two national NHS data sources. Blueteq records applications for high-cost cancer drugs, while the Systemic Anti-Cancer Therapy (SACT) dataset tracks which treatments patients actually receive. The study included 876 adults who started abemaciclib plus fulvestrant between April and December 2019 in England, all with disease that had already grown despite earlier hormone treatment. Using follow-up information to March 2024, the researchers measured how long patients lived (overall survival), how long they went before needing any new cancer drug (treatment-free survival), and how long they went before needing chemotherapy specifically (chemotherapy-free survival).

What happened in everyday NHS care

The findings were sobering. In the English NHS group, people lived a median of 25.9 months after starting abemaciclib plus fulvestrant, compared with 46.7 months in the MONARCH-2 trial—a gap of almost 21 months. The time before needing another cancer treatment was also shorter in real-world care: 11.6 months in the NHS compared with 16.9 months progression-free in MONARCH-2. Patients in England moved on to chemotherapy sooner as well, with a median of 15.3 months before starting it, versus 25.5 months in the trial. More than half of NHS patients eventually received chemotherapy, and when they did, they tended to get it earlier than trial participants.

Looking for reasons behind the gap

The authors investigated several possible explanations. The English patients were somewhat older on average, and a small proportion had poorer physical fitness than would have been allowed into MONARCH-2. However, when the researchers limited their analyses to fitter patients (those with good performance status), survival in the NHS group was still clearly shorter than in the trial. They also examined previous hormone treatment patterns and found particularly poor outcomes for people whose cancer had already grown while they were still on hormone therapy after surgery—an indication of more stubborn disease. Importantly, the trial excluded anyone who had already received chemotherapy for advanced disease or had serious other illnesses, while NHS practice did not. This means the real-world group likely included more heavily pre-treated and medically complex patients, who generally have worse prospects and may switch to chemotherapy sooner.

What this means for patients and policy

Overall, the study shows that the impressive results from the MONARCH-2 trial do not fully carry over to the broader and more varied population treated in England’s NHS. Patients still benefit from abemaciclib plus fulvestrant, but their lives are, on average, shorter and their periods without further treatment or chemotherapy are briefer than the trial suggested. The differences cannot be fully explained by age, sex, or basic fitness alone, pointing instead to real-world factors such as prior treatments, other illnesses, and how doctors and patients decide when to change therapies. For patients and decision-makers, this work highlights the importance of checking how new cancer medicines perform in everyday practice, not just in carefully selected trial groups, so that expectations, guidelines, and funding decisions are grounded in the realities faced by most people with advanced breast cancer.

Citation: Anderson, J., Lawton, S., Thackray, K. et al. Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial. Br J Cancer 134, 1440–1446 (2026). https://doi.org/10.1038/s41416-026-03396-z

Keywords: advanced breast cancer, real-world evidence, abemaciclib, hormone therapy, clinical trials